US2007093443A1PendingUtilityA1

Modified proteases that inhibit complement activation

56
Assignee: MADISON EDWIN LPriority: Oct 21, 2005Filed: Oct 20, 2006Published: Apr 26, 2007
Est. expiryOct 21, 2025(expired)· nominal 20-yr term from priority
Inventors:Edwin L. MadisonJack NguyenSandra Waugh RugglesChristopher D. Thanos
A61P 9/10A61P 37/00A61P 37/02A61P 9/00A61P 25/28A61P 29/00A61P 31/00A61P 31/04A61P 25/00C12N 9/6421C12N 9/64A61P 1/04A61K 38/482A61K 38/43A61K 38/49C12N 9/6467C12N 9/6424C12Y 304/21109C12N 15/62A61K 38/48C07K 2319/00A61P 21/04A61P 1/00A61P 13/12A61P 19/02A61P 11/06
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided are methods for and compounds for modulating the complement system. In particular, compounds are provided that inhibit complement activation and compounds are provided that promote complement activation. The compounds are therapeutics by virtue of their effects on the complement system. Hence, the compounds that inhibit complement activation can be used for treatment of ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, inflammatory diseases and diseases with an inflammatory component, including Alzheimer's Disease and other neurodegenerative disorder.

Claims

exact text as granted — not AI-modified
1 . A method of modulating complement activation, comprising contacting a non-complement protease with any one or more target substrates of a complement pathway, whereby a target substrate protein is cleaved such that complement activation in a pathway comprising the target substrate is altered.  
     
     
         2 . The method of  claim 1 , wherein contacting the non-complement protease with any one or more target substrates of a complement pathway occurs in vitro.  
     
     
         3 . The method of  claim 1 , wherein contacting the non-complement protease with any one or more target substrates of a complement pathway occurs in vivo.  
     
     
         4 . The method of  claim 1 , wherein contacting the non-complement protease with any one or more target substrates of a complement pathway occurs ex vivo.  
     
     
         5 . The method of  claim 1 , wherein complement activation is inhibited.  
     
     
         6 . The method of  claim 1 , wherein complement activation is increased.  
     
     
         7 . The method of  claim 1 , wherein the complement pathway is selected from among one or more of the classical, alternative and lectin pathways of complement.  
     
     
         8 . The method of  claim 1 , wherein the target substrate is any one or more of C1q, C2, C3, iC3, C4, iC4, C5, C6, C7, C8, C9, MBL, Factor B, Factor D, Factor P, MASP-1, MASP-2, C1r, C1s, C4b, C4a, C2b, C2a, C3b, C3a, Ba and Bb.  
     
     
         9 . The method of  claim 1 , wherein the target substrate comprises a sequence of amino acids set forth in any one of SEQ ID NOS: 298, 299, 300, 302, 304, 305, 306, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 326, 328, 330, 332, 334, 335, 338, 340, and 344, or comprises a fragment thereof that exhibits a complement activity.  
     
     
         10 . The method of  claim 1  wherein the target substrate is a ficolin.  
     
     
         11 . The method of  claim 10 , wherein the target substrate comprises a sequence of amino acids set forth in any of SEQ ID NOS: 660-662.  
     
     
         12 . The method of  claim 1 , wherein the non-complement protease comprises modifications at any one or more amino acid residues compared to an unmodified or scaffold protease, wherein the modified amino acid residue(s) increases one or both of specificity for a target substrate or activity towards a target substrate.  
     
     
         13 . The method of  claim 12 , wherein the unmodified or scaffold protease is any one of a serine protease, a cysteine protease, an aspartic protease, a threonine protease, or a metallo-protease.  
     
     
         14 . The method of  claim 13 , wherein the scaffold protease is selected from among proteases selected from among granzyme B, granzyme A, granzyme M, cathepsin G, MT-SP1, neutrophil elastase, chymase, alpha-tryptase, beta-trypsase I or II, chymotrypsin, collagenase, factor XII, factor XI, factor CII, factor X, thrombin, protein C, u-plasminogen activator (u-PA), t-plasminogen activator (t-PA), plasmin, plasma kallikrein, chymotrypsin, trypsin, a cathepsin, papain, cruzain, a metalloprotease and allelic variations, isoforms and catalytically active portions thereof.  
     
     
         15 . The method of  claim 14 , wherein the scaffold protease comprises a sequence of amino acids set forth in any one of SEQ ID NOS: 2, 4, 8, 77, 79, 83, 85, 87, 89, 93, 99, 117, 119, 121, 123, 132, 134, 138, 142, 144, 146, 148, 162, 166, 168, 170, 172, 174, 176, 178, 180, 182, 190, 192, 194, 196, 198, 200, 202, 204, 206, 208, 218, 220, 222, 224, 226, 238, 248, 250, 260, 262, 280, 282, 373, 375, 377, 379, 381, 383, 385, 387, 547, 549, and 551 and catalytically active portions thereof.  
     
     
         16 . The method of  claim 14 , wherein the scaffold protease is an MT-SP1 protease.  
     
     
         17 . The method of  claim 16 , wherein an MT-SP1 protease or a catalytically active portion thereof comprises a sequence of amino acids set forth in SEQ ID NO: 2 or 10, or is an allelic or species variant thereof.  
     
     
         18 . The method of  claim 16 , wherein the target substrate is C2 or C3.  
     
     
         19 . The method of  claim 16 , wherein the modification(s) in an MT-SP1 protease or a catalytically active portion thereof are selected from a protease having a modification in position 224 and/or position 146, based on chymotrypsin numbering.  
     
     
         20 . The method of  claim 18 , wherein the modification(s) in an MT-SP1 protease or a catalytically active portion thereof are selected from a protease having a modification in position 224 and/or position 146, based on chymotrypsin numbering.  
     
     
         21 . The method of  claim 16 , wherein the modification(s) in an MT-SP1 protease or a catalytically active portion thereof are selected from a protease having a modification in position 151, based on chymotrypsin numbering.  
     
     
         22 . The method of  claim 18 , wherein the modification(s) in an MT-SP1 protease or a catalytically active portion thereof are selected from a protease having a modification in position 151, based on chymotrypsin numbering.  
     
     
         23 . The method of  claim 21 , wherein the modification in an MT-SP1 protease or catalytically active portion thereof correspond to a protease having a modification selected from among I41T/Y146D/G151L/K224F, I41T/Y146D/G151L/Q175D/K224F, I41T/Y146D/G151L/Q175D/K224L, I41T/Y146D/G151L/Q175D/K224R, AND I41T/Y146D/G151L/Q175D/K224N, I41T/Y146D/G151L/K224N, Y146D/G151L/K224N, I41T/Y146D/G151L/Q175K/K224F, I41T/Y146D/G151L/Q175R/K224F, I41T/Y146D/G151L/Q175H/K224F, I41T/Y146D/G151L/Q175Y/K224F, I41T/Y146D/G151L/Q175K/K224N, I41T/Y146D/G151L/Q175R/K224N, I41T/Y146D/G151L/Q175H/K224N, and I41T/Y146D/G151L/Q175Y/K224N based on chymotrypsin numbering.  
     
     
         24 . The method of  claim 16 , wherein the modifications in the MT-SP1 protease or a catalytically active portion thereof are in any one or more amino acids that contribute to extended substrate specificity or secondary sites of interaction.  
     
     
         25 . The method of  claim 24 , wherein the modifications in a MT-SP1 protease or a catalytically active portion thereof correspond to any one or more of amino acid positions 97, 146, 192, and 224 of an MT-SP1 protease, based on chymotrypsin numbering.  
     
     
         26 . The method of  claim 25 , wherein the modification(s) in an MT-SP1 protease or a catalytically active portion thereof correspond to any one or more of amino acids F97, Y146, Q192, and K224 of the MT-SP1 protease, based on chymotrypsin numbering.  
     
     
         27 . The method of  claim 26 , wherein the modification(s) in an MT-SP1 protease or a catalytically active portion thereof are selected from any one or more of F97D, F97E, F97A, F97W, Y146N, Y146D, Y146E, Y146A, Y146W, Y146R, Q192R, Q192V, K224A, and K224F.  
     
     
         28 . The method of  claim 16 , wherein the modification(s) in an MT-SP1 protease or a catalytically active portion thereof corresponds to a modified MT-SP1 polypeptide having a sequence of amino acids as set forth in any of SEQ ID NOS: 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40-69, 404-418, 419-447, 524-533, 552-659, or 663-710.  
     
     
         29 . The method of  claim 27 , wherein the modification(s) in an MT-SP1 protease or a catalytically active portion thereof are Y146D/K224F or Y146E.  
     
     
         30 . The method of  claim 28 , wherein the modification(s) in an MT-SP1 protease or a catalytically active portion thereof correspond to a modified MT-SP1 polypeptide having a sequence of amino acids as set forth in SEQ ID NOS: 596 or 650.  
     
     
         31 . The method of  claim 16 , wherein the modification(s) in an MT-SP1 protease or a catalytically active portion thereof are selected from among F97N, F97D, F97E, F99Y, F99V, F99W, D217A, D217V, F97A, F97W, F99A, Y146N, Y146D, Y146E, Y146A, Y146W, Y146R, W215F, W215Y, Q192V, Q192R, Q192F, K224A, K224F, M180E, Y146D/K224F, D96A, Y146E/K224N, I41T/Y146E/Q175D/K224R, I41T/Y146D/K224F, I41T/Y146E/Q175D/K224N, I41T/Y146E/G151L/Q175D/K224L, Y146E/Q221aE/K224F, I41T/Y146E/G151L/Q175D/K224R, I41T/Y146E/G151L/Q175D/K224N, Q221aD, Y146E/K224R, Y146E/Q175D/K224N, Y146D/K224R, I41T/Y146E/G151L/Q175D/K224F, Y146E/Q175D/K224R, Y146E/L224L, G147E, Y146D/Q175D/K224R, Y146D/Q175L/K224L, Y146D/Q175L/K224L, Y146D/Q175W/K224L, Y146D/K224L, Y146E/Q221aE/K224R, Y146E/K224A, Y146D/Q175H/K224L, Y146D/Q175Y/K224L, Y146E/K224Y, Y146D/Q175F/K224L, Y146D/Q175F/K225L, Y146D/Q221aL/K224S, I41E/Y146D/K224L, Y146D/D217F/K224L, Y146D/D217F/K224L, H143V/Y146D/K224F, Y146E/K224F, Y146A/K224F, Y146E/K224T, I41T/Y146E/K224L, I41F/Y146D/K224F, I41L/Y146D/K224F, I41T/Y146D/G151L/K224F, I41A/Y146D/K224F, I41E/Y146D/K224F, I41D/Y146D/K224L, I41D/Y146D/K224F, Y146N/K224F; I41T/Y146D/Q175D/K224F, Q192F/K224F, Y146D/Q192A/K224F, Q192V/K224F, I41T/Y146D/Q175D/K224L, I41T/Y146D/Q175D/K224R, I41T/Y146D/Q175D/K224N, I41T/Y146D/G151L/Q175D/K224F, I41T/Y146D/G151L/Q175D/K224L, I41T/Y146D/G151L/Q175D/K224R, I41T/Y146D/G151L/Q175D/K224N, I41T/Y146E/Q175D/K224F, I41T/Y146E/Q175D/K224L, I41T/Y146D/G151L/K224N, Y146D/Q175D/K224N, Y146D/Q175D/K224N, Y146D/G151L/K224N, Y146D/Q175R/K224N, Y146D/Q175K/K224N, Y146D/Q175H/K224N, I41T/Y146D/G151L/Q175K/K224F, I41T/Y146D/G151L/Q175R/K224F, I41T/Y146D/G151L/Q175H/K224F, I41T/Y146D/G151L/Q175Y/K224F, I41T/Y146D/G151L/Q175K/K224N, I41T/Y146D/G151L/Q175R/K224N, I41T/Y146D/G151L/Q175H/K224N, and I41T/Y146D/G151L/Q175Y/K224N, based on chymotrypsin numbering.  
     
     
         32 . The method of  claim 31 , wherein the MT-SP1 protease cleaves a target substrate at a substrate recognition site.  
     
     
         33 . The method of  claim 32 , wherein the target substrate is C2 or C3.  
     
     
         34 . The method of  claim 33 , wherein the target substrate is C2 and the substrate recognition site includes a sequence of amino acids of SLGR (SEQ ID NO:392).  
     
     
         35 . The method of  claim 1 , wherein the non-complement protease cleaves a substrate recognition site of a target substrate.  
     
     
         36 . The method of  claim 35 , wherein the non-complement protease cleaves a Factor I substrate recognition site.  
     
     
         37 . A method for treating a subject with a complement-mediated disorder, comprising administering a non-complement protease, whereby the non-complement protease cleaves any one or more target substrates of a complement pathway such that complement activation in a pathway comprising the target substrate is altered.  
     
     
         38 . The method of  claim 37 , wherein complement activation is inhibited.  
     
     
         39 . The method of  claim 38 , wherein the inhibition of complement activation leads to a reduction of inflammatory symptoms associated with a complement-mediated disorder selected from among an inflammatory disorder, a neurodegenerative disorder and a cardiovascular disorder.  
     
     
         40 . The method of  claim 39 , wherein the complement-mediated disorder is selected from among sepsis, Rheumatoid arthritis (RA), membranoproliferative glomerulonephritis (MPGN), Multiple Sclerosis (MS), Myasthenia gravis (MG), asthma, inflammatory bowel disease, immune complex (IC)-mediated acute inflammatory tissue injury, Alzheimer's Disease (AD), and Ischemia-reperfusion injury.  
     
     
         41 . The method of  claim 39 , wherein the complement-mediated disorder is Guillan-Barre syndrome.  
     
     
         42 . The method  claim 40 , wherein the ischemia-reperfusion injury is caused by an event or treatment selected from among myocardial infarct (MI), stroke, angioplasty, coronary artery bypass graft, cardiopulmonary bypass (CPB), and hemodialysis.  
     
     
         43 . The method of claims  37 , wherein the complement-mediated disorder results from a treatment of a subject.  
     
     
         44 . The method of  claim 43 , wherein administering a non-complement protease is effected prior to treatment of a subject.  
     
     
         45 . The method of  claim 37 , wherein administering a non-complement protease is effected by contacting a body fluid or tissue sample in vitro, ex vivo, or in vivo with a non-complement protease.  
     
     
         46 . The method of  claim 43 , wherein the treatment results in complement-mediated ischemia-reperfusion injury.  
     
     
         47 . The method of  claim 46 , wherein the treatment is angioplasty or coronary artery bypass graft.  
     
     
         48 . The method of  claim 37 , wherein the complement pathway is one or more of the classical, alternative and lectin pathways.  
     
     
         49 . The method of  claim 37 , wherein the target substrate is any one or more of C1q, C2, C3, iC3, C4, iC4, C5, C6, C7, C8, C9, MBL, Factor B, Factor D, Factor P, MASP-1, MASP-2, C1r, C1s, C4b, C4a, C2b, C2a, C3b, C3a, Ba and Bb.  
     
     
         50 . The method of any of  claim 37 , wherein the target substrate comprises a sequence of amino acids set forth in any one of SEQ ID NOS: 298, 299, 300, 302, 304, 305, 306, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 326, 328, 330, 332, 334, 335, 338, 340, or 344, or comprises a fragment thereof that exhibits a complement activity.  
     
     
         51 . The method of claims  37 , wherein the target substrate is ficolin.  
     
     
         52 . The method of  claim 49 , wherein the non-complement protease comprises modifications at any one or more amino acid residues compared to an unmodified or scaffold protease, wherein the modified amino acid residue(s) increases one or both of specificity for a target substrate or activity towards a target substrate.  
     
     
         53 . The method of  claim 52 , wherein the unmodified or scaffold protease is any one of a serine protease, cysteine protease, aspartic protease, threonine protease, or metallo-protease.  
     
     
         54 . The method of  claim 53 , wherein the scaffold protease is is selected from among proteases selected from among granzyme B, granzyme A, granzyme M, cathepsin G, MT-SP1, neutrophil elastase, chymase, alpha-tryptase, beta-trypsase I or II, chymotrypsin, collagenase, factor XII, factor XI, factor CII, factor X, thrombin, protein C, u-plasminogen activator (u-PA), t-plasminogen activator (t-PA), plasmin, plasma kallikrein, chymotrypsin, trypsin, a cathepsin, papain, cruzain, a metalloprotease and allelic variations, isoforms and catalytically active portions thereof.  
     
     
         55 . The method of  claim 54 , wherein the scaffold protease comprises a sequence of amino acids as set forth in any one of SEQ ID NOS: 2, 4, 8, 77, 79, 83, 85, 87, 89, 93, 99, 117, 119, 121, 123, 132, 134, 138, 142, 144, 146, 148, 162, 166, 168, 170, 172, 174, 176, 178, 180, 182, 190, 192, 194, 196, 198, 200, 202, 204, 206, 208, 218, 220, 222, 224, 226, 238, 248, 250, 260, 262, 280, 282, 373, 375, 377, 379, 381, 383, 385, 387, 547, 549, and 551 and catalytically active portions thereof.  
     
     
         56 . The method of  claim 54 , wherein the scaffold protease is an MT-SP1 protease.  
     
     
         57 . The method of  claim 56 , wherein an MT-SP1 protease or a catalytically active portion thereof comprises a sequence of amino acids set forth in SEQ ID NO: 2 or 10, or is an allelic or species variant thereof.  
     
     
         58 . The method of  claim 56 , wherein the target substrate is C2 or C3.  
     
     
         59 . The method of  claim 56 , wherein the modification(s) in an MT-SP1 protease or a catalytically active portion thereof comprises a modification in position 224, based on chymotrypsin numbering.  
     
     
         60 . The method of  claim 58 , wherein the modification(s) in an MT-SP1 protease or a catalytically active portion thereof comprises a modification in position 224, based on chymotrypsin numbering.  
     
     
         61 . The method of  claim 56 , wherein the modification(s) in an MT-SP1 protease or a catalytically active portion thereof comprises a modification in position 151, based on chymotrypsin numbering.  
     
     
         62 . The method of  claim 58 , wherein the modification(s) in an MT-SP1 protease or a catalytically active portion thereof comprises a modification in position 151, based on chymotrypsin numbering.  
     
     
         63 . The method of  claim 51 , wherein the modification in an MT-SP1 protease or catalytically active portion thereof is selected from among I41T/Y146D/G151L/K224F, I41T/Y146D/G151L/Q175D/K224F, I41T/Y146D/G151L/Q175D/K224L, I41T/Y146D/G151L/Q175D/K224R, AND I41T/Y146D/G151L/Q175D/K224N, I41T/Y146D/G151L/K224N, Y146D/G151L/K224N, I41T/Y146D/G151L/Q175K/K224F, I41T/Y146D/G151L/Q175R/K224F, I41T/Y146D/G151L/Q175H/K224F, I41T/Y146D/G151L/Q175Y/K224F, I41T/Y146D/G151L/Q175K/K224N, I41T/Y146D/G151L/Q175R/K224N, I41T/Y146D/G151L/Q175H/K224N, and I41T/Y146D/G151L/Q175Y/K224N based on chymotrypsin numbering.  
     
     
         64 . The method of  claim 56 , wherein the modification(s) in an MT-SP1 protease or a catalytically active portion thereof are in any one or more amino acids that contribute to extended substrate specificity or secondary sites of interaction.  
     
     
         65 . The method of  claim 64 , wherein the modification(s) in an MT-SP1 protease or a catalytically active portion thereof correspond to any one or more of amino acid positions 97, 146, 192, and 224 of an MT-SP1 protease, based on chymotrypsin numbering.  
     
     
         66 . The method of  claim 65 , wherein the modification(s) in an MT-SP1 protease or a catalytically active portion thereof correspond to any one or more of amino acids F97, Y146, Q192, and K224 of the MT-SP1 protease, based on chymotrypsin numbering.  
     
     
         67 . The method of  claim 66 , wherein the modification(s) in an MT-SP1 protease or a catalytically active portion thereof are selected from any one or more of F97D, F97E, F97A, F97W, Y146N, Y146D, Y146E, Y146A, Y146W, Y146R, Q192R, Q192V, K224A, and K224F.  
     
     
         68 . The method of  claim 56 , wherein the modification(s) in an MT-SP1 protease or a catalytically active portion thereof corresponds to a modified MT-SP1 polypeptide having a sequence of amino acids as set forth in any of SEQ ID NOS: 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40-69, 404-418, 419-447, 524-533, 552-659, or 663-710.  
     
     
         69 . The method of  claim 67 , wherein the modification(s) in an MT-SP1 protease or a catalytically active portion thereof are Y146D/K224F or Y146E.  
     
     
         70 . The method of  claim 68 , wherein the modification(s) in an MT-SP1 protease or a catalytically active portion thereof correspond to a modified MT-SP1 polypeptide having a sequence of amino acids as set forth in SEQ ID NO:596 or 650.  
     
     
         71 . The method of  claim 56 , wherein the modification(s) in an MT-SP1 protease or a catalytically active portion thereof are selected from among F97N, F97D, F97E, F99Y, F99V, F99W, D217A, D217V, F97A, F97W, F99A, Y146N, Y146D, Y146E, Y146A, Y146W, Y146R, W215F, W215Y, Q192V, Q192R, Q192F, K224A, K224F, M180E, Y146D/K224F, D96A, Y146E/K224N, I41T/Y146E/Q175D/K224R, I41T/Y146D/K224F, I41T/Y146E/Q175D/K224N, I41T/Y146E/G151L/Q175D/K224L, Y146E/Q221aE/K224F, I41T/Y146E/G151L/Q175D/K224R, I41T/Y146E/G151L/Q175D/K224N, Q221aD, Y146E/K224R, Y146E/Q175D/K224N, Y146D/K224R, I41T/Y146E/G151L/Q175D/K224F, Y146E/Q175D/K224R, Y146E/L224L, G147E, Y146D/Q175D/K224R, Y146D/Q175L/K224L, Y146D/Q175L/K224L, Y146D/Q175W/K224L, Y146D/K224L, Y146E/Q221aE/K224R, Y146E/K224A, Y146D/Q175H/K224L, Y146D/Q175Y/K224L, Y146E/K224Y, Y146D/Q175F/K224L, Y146D/Q175F/K225L, Y146D/Q221aL/K224S, I41E/Y146D/K224L, Y146D/D217F/K224L, Y146D/D217F/K224L, H143V/Y146D/K224F, Y146E/K224F, Y146A/K224F, Y146E/K224T, I41T/Y146E/K224L, I41F/Y146D/K224F, I41L/Y146D/K224F, I41T/Y146D/G151L/K224F, I41A/Y146D/K224F, I41E/Y146D/K224F, I41D/Y146D/K224L, I41D/Y146D/K224F, Y146N/K224F, I41T/Y146D/Q175D/K224F, Q192F/K224F, Y146D/Q192A/K224F, Q192V/K224F, I41T/Y146D/Q175D/K224L, I41T/Y146D/Q175D/K224R, I41T/Y146D/Q175D/K224N, I41T/Y146D/G151L/Q175D/K224F, I41T/Y146D/G151L/Q175D/K224L, I41T/Y146D/G151L/Q175D/K224R, I41T/Y146D/G151L/Q175D/K224N, I41T/Y146E/Q175D/K224F, I41T/Y146E/Q175D/K224L, I41T/Y146D/G151L/K224N, Y146D/Q175D/K224N, Y146D/Q175D/K224N, Y146D/G151L/K224N, Y146D/Q175R/K224N, Y146D/Q175K/K224N, Y146D/Q175H/K224N, I41T/Y146D/G151L/Q175K/K224F, I41T/Y146D/G151L/Q175R/K224F, I41T/Y146D/G151L/Q175H/K224F, I41T/Y146D/G151L/Q175Y/K224F, I41T/Y146D/G151L/Q175K/K224N, I41T/Y146D/G151L/Q175R/K224N, I41T/Y146D/G151L/Q175H/K224N, and I41T/Y146D/G151L/Q175Y/K224N, based on chymotrypsin numbering.  
     
     
         72 . The method of  claim 71 , wherein the MT-SP1 protease cleaves a substrate recognition site of the target substrate.  
     
     
         73 . The method of  claim 72 , wherein the target substrate is C2 or C3.  
     
     
         74 . The method of  claim 73 , wherein the target substrate is C2 and the substrate recognition site includes a sequence of amino acids of SLGR (SEQ ID NO:392).  
     
     
         75 . The method of  claim 37 , wherein the non-complement protease cleaves a substrate recognition site of the target substrate.  
     
     
         76 . The method of  claim 75 , wherein the non-complement protease cleaves a Factor I substrate recognition site.  
     
     
         77 . The method of  claim 37 , wherein the non-complement protease or a catalytically active portion thereof is administered in combination with a second agent for treating a complement-mediated disorder.  
     
     
         78 . The method of  claim 77 , wherein the second agent is an anti-inflammatory agent or an anticoagulant.  
     
     
         79 . The method of  claim 78 , wherein the second agent is selected from among any one or more of a NSAID, antimetabolite, corticosteroid, analgesic, cytotoxic agent, pro-inflammatory cytokine inhibitor, anti-inflammatory cytokines, B cell targeting agents, compounds targeting T antigens, adhesion molecule blockers, chemokines receptor antagonists, kinase inhibitors, PPAR-γ ligands, complement inhibitors, heparin, warfarin, acenocoumarol, phenindione, EDTA, citrate, oxalate, argatroban, lepirudin, bivalirudin, and ximelagatran.  
     
     
         80 . A combination, comprising: 
 (a) a non-complement protease that cleaves any one or more complement target substrates of a complement pathway such that complement activation in a pathway comprising the target substrate is altered; and    (b) a second agent or agents for treating a complement-mediated disorder.    
     
     
         81 . The combination of  claim 80 , wherein the second agent or agents is an anti-inflammatory agent(s) or anticoagulant(s).  
     
     
         82 . The combination of  claim 81  wherein, the anti-inflammatory agent(s) is selected from among any one or more of a NSAID, antimetabolite, corticosteroid, analgesic, cytotoxic agent, pro-inflammatory cytokine inhibitor, anti-inflammatory cytokines, B cell targeting agents, compounds targeting T antigens, adhesion molecule blockers, chemokines receptor antagonists, kinase inhibitors, PPAR-γ ligands, complement inhibitors, heparin, warfarin, acenocoumarol, phenindione, EDTA, citrate, oxalate, argatroban, lepirudin, bivalirudin, and ximelagatran.  
     
     
         83 . The combination of  claim 80 , wherein complement activation is inhibited.  
     
     
         84 . A modified non-complement protease, comprising modifications in any one or more amino acids of a scaffold protease, wherein: 
 the modified amino acid residue(s) increases one or both of specificity for a target substrate or activity towards a target substrate, wherein the target substrate is a complement protein.    
     
     
         85 . The modified non-complement protease of  claim 84 , wherein the target substrate is any one or more of C1q, C2, C3, iC3, C4, iC4, C5, C6, C7, C8, C9, MBL, Factor B, Factor D, Factor P, MASP-1, MASP-2, C1r, C1s, C4b, C4a, C2b, C2a, C3b, C3a, Ba, or Bb.  
     
     
         86 . The modified non-complement protease of  claim 84 , wherein the target substrate comprises a sequence of amino acids set forth in any one SEQ ID NOS: 298, 299, 300, 302, 304, 305, 306, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 326, 328, 330, 332, 334, 335, 338, 340, and 344, or comprises a fragment thereof that exhibits a complement activity.  
     
     
         87 . The modified non-complement protease of  claim 84 , wherein the target substrate is a ficolin.  
     
     
         88 . The modified non-complement protease of  claim 87 , wherein the target substrate comprises a sequence of amino acids set forth in any of SEQ ID NOS:660-662.  
     
     
         89 . The modified non-complement protease of  claim 84 , wherein the scaffold protease is selected from among a serine protease, cysteine protease, aspartic protease, threonine protease, and metallo-protease.  
     
     
         90 . The modified non-complement protease of  claim 89 , wherein the scaffold protease is selected from among granzyme B, granzyme A, granzyme M, cathepsin G, MT-SP1, neutrophil elastase, chymase, alpha-tryptase, beta-trypsase I or II, chymotrypsin, collagenase, factor XII, factor XI, factor CII, factor X, thrombin, protein C, u-plasminogen activator (u-PA), t-plasminogen activator (t-PA), plasmin, plasma kallikrein, chymotrypsin, trypsin, a cathepsin, papain, cruzain, a metalloprotease and allelic variations, isoforms and catalytically active portions thereof.  
     
     
         91 . The modified non-complement protease of  claim 90 , wherein the scaffold protease comprises a sequence of amino acids as set forth in any one of SEQ ID NOS: 2, 4, 8, 77, 79, 83, 85, 87, 89, 93, 99, 117, 119, 121, 123, 132, 134, 138, 142, 144, 146, 148, 162, 166, 168, 170, 172, 174, 176, 178, 180, 182, 190, 192, 194, 196, 198, 200, 202, 204, 206, 208, 218, 220, 222, 224, 226, 238, 248, 250, 260, 262, 280, 282, 373, 375, 377, 379, 381, 383, 385, 387, 547, 549, and 551 and catalytically active portions thereof.  
     
     
         92 . The modified non-complement protease of  claim 90 , wherein the scaffold protease is an MT-SP1 protease.  
     
     
         93 . The modified non-complement protease of  claim 92 , wherein the MT-SP1 protease or a catalytically active portion thereof comprises a sequence of amino acids set forth in SEQ ID NO: 2 or 10.  
     
     
         94 . The modified non-complement protease of claims  92 , wherein the target substrate is C2 or C3.  
     
     
         95 . The modified non-complement protease of  claim 92 , comprising at least two or more modifications, wherein one modification is at position 146 and the second modification is at position 224, based on chymotrypsin numbering, provided that: 
 (i) where the protease includes only two modifications, the protease does not include Y146D and K224F as the two modification; and    (ii) where the protease contains three modifications, the protease does not include F99V or I or L or T with Y146D and K224F.    
     
     
         96 . The modified non-complement protease of  claim 94 , comprising at least two or more modifications, wherein one modification is a position 146 and the second is at position 224, based on chymotrypsin numbering, provided that: 
 (i) where the protease includes only two modifications, the protease does not include Y146D and K224F as the two modification; and    (ii) where the protease contains three modifications, the protease does not include F99V or I or L or T with Y146D and K224F.    
     
     
         97 . The modified non-complement protease of  claim 92 , comprising at least one modification at position 151, based on chymotrypsin numbering.  
     
     
         98 . The modified non-complement protease of  claim 94 , comprising at least one modification at position 151, based on chymotrypsin numbering.  
     
     
         99 . The modified non-complement protease of  claim 97 , wherein modification(s) in an MT-SP1 or catalytically active portion are selected from among I41T/Y146D/G151L/K224F, I41T/Y146D/G151L/Q175D/K224F, I41T/Y146D/G151L/Q175D/K224L, I41T/Y146D/G151L/Q175D/K224R, AND I41T/Y146D/G151L/Q175D/K224N, I41T/Y146D/G151L/K224N, Y146D/G151L/K224N, I41T/Y146D/G151L/Q175K/K224F, I41T/Y146D/G151L/Q175R/K224F, I41T/Y146D/G151L/Q175H/K224F, I41T/Y146D/G151L/Q175Y/K224F, I41T/Y146D/G151L/Q175K/K224N, I41T/Y146D/G151L/Q175R/K224N, I41T/Y146D/G151L/Q175H/K224N, and I41T/Y146D/G151L/Q175Y/K224N based on chymotrypsin numbering.  
     
     
         100 . The modified non-complement protease of  claim 99 , wherein modification(s) in an MT-SP1 or catalytically active portion correspond to modification of I41T/I46D/G151L/K224F, based on chymotrypsin numbering.  
     
     
         101 . The modified non-complement protease of  claim 92 , wherein modification(s) in an MT-SP1 protease or a catalytically active portion thereof are selected from any one or more of D96A, D96V, D96F, D96F, D96S, D96T, F99S, F99G, Q174H, Q174A, Q174V, Q174F, Q174R, Q174K, Q174L, Q174Y, Q192L, Q192I, Q192E, Q192K, Q192Y, D217Q, D217N, D217H, K224A, based on chymotrypsin numbering.  
     
     
         102 . The modified non-complement protease of  claim 92 , wherein modification(s) in an MT-SP1 protease or a catalytically active portion thereof are selected from among Y146E/K224N, I41T/Y146E/Q175D/K224R, I41T/Y146D/K224F, I41T/Y146E/Q175D/K224N, I41T/Y146E/G151L/Q175D/K224L, Y146E/Q221aE/K224F, I41T/Y146E/G151L/Q175D/K224R, I41T/Y146E/G151L/Q175D/K224N, Q221aD, Y146E/K224R, Y146E/Q175D/K224N, Y146D/K224R, I41T/Y146E/G151L/Q175D/K224F, Y146E/Q175D/K224R, Y146E/L224L, G147E, Y146D/Q175D/K224R, Y146D/Q175L/K224L, Y146D/Q175L/K224L, Y146D/Q175W/K224L, Y146D/K224L, Y146E/Q221aE/K224R, Y146E/K224A, Y146D/Q175H/K224L, Y146D/Q175Y/K224L, Y146E/K224Y, Y146D/Q175F/K224L, Y146D/Q175F/K225L, Y146D/Q221aL/K224S, I41E/Y146D/K224L, Y146D/D217F/K224L, Y146D/D217F/K224L, H143V/Y146D/K224F, Y146E/K224F, Y146A/K224F, Y146E/K224T, I41T/Y146E/K224L, I41F/Y146D/K224F, I41L/Y146D/K224F, I41T/Y146D/G151L/K224F, I41A/Y146D/K224F, I41E/Y146D/K224F, I41D/Y146D/K224L, I41D/Y146D/K224F, Y146N/K224F, I41T/Y146D/Q175D/K224F, Q192F/K224F, Y146D/Q192A/K224F, Q192V/K224F, I41T/Y146D/Q175D/K224L, I41T/Y146D/Q175D/K224R, I41T/Y146D/Q175D/K224N, I41T/Y146D/G151L/Q175D/K224F, I41T/Y146D/G151L/Q175D/K224L, I41T/Y146D/G151L/Q175D/K224R, I41T/Y146D/G151L/Q175D/K224N, I41T/Y146E/Q175D/K224F, and I41T/Y146E/Q175D/K224L, I41T/Y146D/G151L/K224N, Y146D/Q175D/K224N, Y146D/Q175D/K224N, Y146D/G151L/K224N, Y146D/Q175R/K224N, Y146D/Q175K/K224N, Y146D/Q175H/K224N, I41T/Y146D/G151L/Q175K/K224F, I41T/Y146D/G151L/Q175R/K224F, I41T/Y146D/G151L/Q175H/K224F, I41T/Y146D/G151L/Q175Y/K224F, I41T/Y146D/G151L/Q175K/K224N, I41T/Y146D/G151L/Q175R/K224N, I41T/Y146D/G151L/Q175H/K224N, and I41T/Y146D/G151L/Q175Y/K224N, based on chymotrypsin numbering.  
     
     
         103 . The modified non-complement protease of  claim 92 , wherein the modification(s) in an MT-SP1 protease or a catalytically active portion thereof correspond to a modified MT-SP1 polypeptide having a sequence of amino acids as set forth in any one of SEQ ID NOS: 41-51, 56, 57, 60-64, 67, 69, 419-429, 431, 434, 435, 438-442, 445, 524, 525, 527-530, 532, 533, 552-659, or 663-710.  
     
     
         104 . The modified non-complement protease of  claim 92 , wherein the modification(s) in an MT-SP1 protease or a catalytically active portion thereof correspond to a modified MT-SP1 polypeptide having a sequence of amino acids as set forth in any one of SEQ ID NOS: 596 or 650.  
     
     
         105 . The modified non-complement protease of  claim 103 , wherein the MT-SP1 protease cleaves a substrate recognition site of the target substrate.  
     
     
         106 . The modified non-complement protease of  claim 105 , wherein the target substrate is C2 or C3.  
     
     
         107 . The modified non-complement protease of  claim 106 , wherein the target substrate is C2 and the substrate recognition site includes a sequence of amino acids of SLGR (SEQ ID NO:392).  
     
     
         108 . A pharmaceutical composition, comprising a modified non-complement protease of  claim 84 .  
     
     
         109 . A combination, comprising: 
 (a) a pharmaceutical composition of  claim 108;  and    (b) a second agent or agents for treating a complement-mediated disorder.    
     
     
         110 . The pharmaceutical composition of  claim 108 , further comprising a pharmaceutically acceptable excipient.  
     
     
         111 . The pharmaceutical composition of 110, wherein the pharmaceutical composition is formulated for systemic, oral, nasal, pulmonary, local, or topical administration.  
     
     
         112 . A kit, comprising the pharmaceutical composition of  claim 108 , a device for administration of the composition and, optionally, instructions for administration.  
     
     
         113 . A nucleic acid molecule, comprising a sequence of nucleotides that encodes any one of the modified non-complement proteases of  claim 84 .  
     
     
         114 . A vector, comprising the nucleic acid molecule of  claim 113 .  
     
     
         115 . A cell, comprising the vector of  claim 114 .  
     
     
         116 . A method of treatment, comprising administering to a subject a nucleic acid molecule of  claim 113 .  
     
     
         117 . The method of treatment of  claim 116 , wherein the nucleic acid molecule is introduced into a vector for administration.  
     
     
         118 . The method of treatment of  claim 117 , wherein the vector is an expression vector.  
     
     
         119 . The method of treatment of  claim 118 , wherein the vector is episomal.  
     
     
         120 . The method of treatment of  claim 117 , wherein the expression vector is selected from among an adenovirus vector, an adeno-associated virus vector, EBV, SV40, cytomegalovirus vector, vaccinia virus vector, herpesvirus vector, a retrovirus vector, a lentivirus vector, or an artificial chromosome.  
     
     
         121 . The method of treatment of claims  117 , wherein the nucleic acid is administered in vivo or ex vivo.  
     
     
         122 . The method of treatment of  claim 121 , wherein ex vivo treatment comprises administering the nucleic acid into a cell in vitro, followed by administration of the cell into the subject.  
     
     
         123 . The method of treatment of  claim 122 , wherein the cell is from a suitable donor or from the subject to be treated.  
     
     
         124 . The method of treatment of  claim 116 , wherein the subject is a human.  
     
     
         125 . A fusion protein, comprising a catalytically active portion of a protease of  claim 84  that is fused to a non-protease polypeptide.  
     
     
         126 . The method of  claim 16 , wherein the modification(s) in an MT-SP1 protease or a catalytically active portion thereof are selected from a protease having a modification in position 41, based on chymotrypsin numbering.  
     
     
         127 . The method of  claim 18 , wherein the modification(s) in an MT-SP1 protease or a catalytically active portion thereof are selected from a protease having a modification in position 41, based on chymotrypsin numbering.  
     
     
         128 . The method of  claim 56 , wherein the modification(s) in an MT-SP1 protease or a catalytically active portion thereof comprises a modification in position 41, based on chymotrypsin numbering.  
     
     
         129 . The method of  claim 58 , wherein the modification(s) in an MT-SP1 protease or a catalytically active portion thereof comprises a modification in position 41, based on chymotrypsin numbering.  
     
     
         130 . The modified non-complement protease of  claim 92 , comprising at least one modification at position 41, based on chymotrypsin numbering.  
     
     
         131 . The modified non-complement protease of  claim 94 , comprising at least one modification at position 41, based on chymotrypsin numbering.

Join the waitlist — get patent alerts

Track US2007093443A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.